Generic Name and Formulations:
Luliconazole 1%; cream.
Valeant Pharmaceuticals, Inc
Indications for LUZU:
Interdigital tinea pedis, t. cruris, and t. corporis caused by Trichophyton rubrum and Epidermophyton floccosum.
≥18yrs: Apply to affected area and approximately 1 inch of the immediate surrounding area(s) once daily. T. pedis: treat for 2 weeks. T. cruris and t. corporis: treat for 1 week.
<18yrs: not established.
Not for ophthalmic, oral, or intravaginal use. Pregnancy. Nursing mothers.
T. pedis, t. cruris: may inhibit CYP2C19 and CYP3A4 activity.
Application site reactions.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Effectiveness of Exercise in Decreasing Depressive Symptoms
- Obsessive Compulsive Disorder Associated With Decreased Educational Attainment
- Neuroactive Steroids May Be Therapeutic Targets for Depression and Anxiety
- Antidepressant Effectiveness for Depression in Schizophrenia
- Dementia Risk Not Associated With Proton Pump Inhibitor Use
- Nutritional Psychiatry: Emerging Evidence and Expert Interview
- Bipolar Disorder, Borderline Personality Disorder May Represent the Same Disorder
- FDA Approval: Once-Monthly Buprenorphine Injection for Opioid Use Disorder
- Posttreatment Brain Effects of Psilocybin in Patients With Treatment-Resistant Depression
- Borderline Personality Disorder: Not Just an Adult Condition
- Psychosis Treatment Failure More Common in Patients With ASD
- Psychiatric Risk for Female Offspring of World War II Finnish Evacuees
- Making a Decision: Using Conscious vs Unconscious Thinking to Solve the Problem
- Adult ADHD May Negatively Affect Fibromyalgia-Related Morbidity
- Depression Screening Tools Accurate in Post-Acute Coronary Syndrome